Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Cash from Operations (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Cash from Operations for 7 consecutive years, with 169773000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations fell 69.99% year-over-year to 169773000.0, compared with a TTM value of 650441000.0 through Dec 2025, down 116.19%, and an annual FY2025 reading of 650441000.0, down 116.19% over the prior year.
  • Cash from Operations was 169773000.0 for Q4 2025 at Avidity Biosciences, down from 156173000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 16501000.0 in Q4 2023 and bottomed at 199666000.0 in Q2 2025.
  • Average Cash from Operations over 5 years is 65072800.0, with a median of 44078000.0 recorded in 2022.
  • The sharpest move saw Cash from Operations skyrocketed 142.11% in 2023, then tumbled 705.24% in 2024.
  • Year by year, Cash from Operations stood at 26215000.0 in 2021, then crashed by 49.49% to 39189000.0 in 2022, then surged by 142.11% to 16501000.0 in 2023, then crashed by 705.24% to 99871000.0 in 2024, then crashed by 69.99% to 169773000.0 in 2025.
  • Business Quant data shows Cash from Operations for RNA at 169773000.0 in Q4 2025, 156173000.0 in Q3 2025, and 199666000.0 in Q2 2025.